21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other molecule...
21:37 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Cell culture and mouse studies identified a peptide-based antagonist of the OPRD1/MOR heterodimer that could help treat opiate withdrawal. Chemical synthesis and testing in cell-based competitive binding and activity assays of conjugates linking OPRD1...
17:49 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest PENK-derived peptides alone or in combination with morphine could help treat pain. In a mouse model of heat-induced pain, intrathecal injection of BAM22, an endogenous PENK-derived peptide, decreased pain-like behaviors compared...
17:01 , May 25, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes no for Insys' analgesic

An FDA panel voted 18-1 that the benefits of Buvaya buprenorphine sublingual spray from Insys Therapeutics Inc. (NASDAQ:INSY) do not outweigh its risks, and thus recommended against the analgesic’s approval. The vote came at a...
19:21 , May 18, 2018 |  BC Extra  |  Company News

FDA reviewers cast doubt on Insys analgesic's utility, safety

FDA reviewers said data from an NDA of Buvaya buprenorphine sublingual spray from Insys Therapeutics Inc. (NASDAQ:INSY) do not support its usage to treat acute pain. The remarks came in briefing documents issued ahead of...
20:58 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other molecule...
00:56 , Feb 14, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Mouse studies suggest inhibiting RGS20 could help treat morphine addiction. In periaqueductal gray samples from morphine-treated mice, levels of RGS20 protein were higher than in samples from vehicle-treated mice. In mice treated with intraperitoneal...
18:39 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA tentatively approves abuse deterrent claim for Egalet's Arymo ER

Egalet Corp. (NASDAQ:EGLT) said FDA granted tentative approval to an expanded label for Arymo ER morphine sulfate extended-release tablets to include data from a Category 2/3 intranasal human abuse potential study and an intranasal abuse...
18:51 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Durect's Posimir misses in Phase III for postsurgical pain

Durect Corp. (NASDAQ:DRRX) said Posimir bupivacaine (SABER-Bupivacaine) missed the primary endpoint in the Phase III PERSIST trial to treat postsurgical pain. The company had expected the trial to support an NDA resubmission following its receipt...
19:52 , Sep 22, 2017 |  BC Week In Review  |  Company News

Daiichi, Inovalon exploring abuse-deterrent opioid outcomes

Daiichi Sankyo Co. Ltd. (Tokyo:4568) partnered with Inovalon Holdings Inc. (NASDAQ:INOV) to use Inovalon’s MORE2 Registry and Inovalon ONE platform to identify outcomes for abuse-deterrent opioids that would be valuable to health plans and then...